Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAF V600E mutation treated with dabrafenib-trametinib: a case report.

Autor: Martín-Soberón MC; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain. mcms.207@gmail.com., Ruiz S; Nuclear Medicine Department, University Hospital 12 de Octubre, Madrid, Spain., De Velasco G; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Yarza R; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Carretero A; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Castellano D; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Sepúlveda-Sánchez JM; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
Jazyk: angličtina
Zdroj: Journal of medical case reports [J Med Case Rep] 2021 Mar 02; Vol. 15 (1), pp. 109. Date of Electronic Publication: 2021 Mar 02.
DOI: 10.1186/s13256-020-02581-9
Abstrakt: Background: Pneumatosis intestinalis (PI) is a rare entity which refers to the presence of gas within the wall of the small bowel or colon which is a radiographic sign. The etiology and clinical presentation are variable. Patients with PI may present either with chronic mild non-specific symptoms or with acute abdominal pain with peritonitis. Some cases of intestinal pneumatosis have been reported as adverse events of new oncological treatments such as targeted therapies that are widely used in multiple tumors.
Case Presentation: A 59-year-old caucasian female with radioactive iodine-refractory metastatic thyroid papillary carcinoma with BRAF V600E mutation was treated with dabrafenib and trametinib as a compassionate use. After 4 months treatment, positron emission tomography-computed tomography (PET-CT) showed PI. At the time of diagnosis, the patient was asymptomatic without signs of peritonitis. The initial treatment was conservative and no specific treatment for PI was needed. Unfortunately, after dabrafenib-trametinib withdrawal, the patient developed tumor progression with significant clinical worsening.
Conclusions: This case report is, in our knowledge, the first description of PI in a patient treated with dabrafenib-trametinib. Conservative treatment is feasible if there are no abdominal symptoms.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje